These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 33901739)

  • 1. A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia.
    Brandts J; Dharmayat KI; Vallejo-Vaz AJ; Azar Sharabiani MT; Jones R; Kastelein JJP; Raal FJ; Ray KK
    Atherosclerosis; 2021 May; 325():46-56. PubMed ID: 33901739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
    Glueck CJ; Shah P; Goldenberg N; Prince M; Lee K; Jetty V; Kumar A; Goldenberg M; Wang P
    Lipids Health Dis; 2016 Mar; 15():55. PubMed ID: 26968977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries.
    Arca M; Celant S; Olimpieri PP; Colatrella A; Tomassini L; D'Erasmo L; Averna M; Zambon A; Catapano AL; Russo P
    J Am Heart Assoc; 2023 Nov; 12(21):e026550. PubMed ID: 37850449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia.
    Tomlinson B; Patil NG; Fok M; Lam CWK
    Endocrinol Metab (Seoul); 2021 Apr; 36(2):279-295. PubMed ID: 33866776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Arca M
    Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center.
    Shah P; Glueck CJ; Jetty V; Goldenberg N; Rothschild M; Riaz R; Duhon G; Wang P
    Lipids Health Dis; 2016 Aug; 15(1):132. PubMed ID: 27538393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Heterozygous familial hypercholesterolemia: the first challenge for anti-PCSK9 monoclonal antibodies].
    Zambon A
    G Ital Cardiol (Rome); 2016 Apr; 17(4 Suppl 1):22S-30. PubMed ID: 27312020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: A retrospective, single center, observational study.
    D'Erasmo L; Commodari D; Di Costanzo A; Minicocci I; Polito L; Ceci F; Montali A; Maranghi M; Arca M
    Nutr Metab Cardiovasc Dis; 2020 Oct; 30(11):2027-2035. PubMed ID: 32830020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapies for familial hypercholesterolemia.
    Mohamed F; Seedat F; Raal FJ
    Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):188-195. PubMed ID: 33278127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia.
    Hovingh GK; Raal FJ; Dent R; Stefanutti C; Descamps O; Masana L; Lira A; Bridges I; Coll B; Sullivan D
    J Clin Lipidol; 2017; 11(6):1448-1457. PubMed ID: 29066265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study.
    Daniels S; Caprio S; Chaudhari U; Manvelian G; Baccara-Dinet MT; Brunet A; Scemama M; Loizeau V; Bruckert E
    J Clin Lipidol; 2020; 14(3):322-330.e5. PubMed ID: 32331936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy].
    Scheen AJ; Wallemacq C; Lancellotti P
    Rev Med Liege; 2022 Dec; 77(12):745-751. PubMed ID: 36484754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab.
    White CM
    Ann Pharmacother; 2015 Dec; 49(12):1327-35. PubMed ID: 26424774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations.
    Hopkins PN; Krempf M; Bruckert E; Donahue S; Yang F; Zhang Y; DiCioccio AT
    J Clin Lipidol; 2019; 13(6):970-978. PubMed ID: 31767518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial.
    Dufour R; Hovingh GK; Guyton JR; Langslet G; Baccara-Dinet MT; Din-Bell C; Manvelian G; Farnier M
    J Clin Lipidol; 2019; 13(1):138-147. PubMed ID: 30591415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Inclisiran in Patients Having Familial Hypercholesterolemia: Heterozygous Compared to Homozygous Trait, a Systematic Review and Meta-analysis.
    Rai R; Devi P; Kumar K; Naeem K; Kumar H; Kumari K; Kumar A; Kumar A; Muhammad A; Khan MS; Qadir G; Ali S; Maheshwari M; Jawwad M
    Crit Pathw Cardiol; 2024 Jun; 23(2):73-80. PubMed ID: 38446086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia.
    Kastelein JJ; Hovingh GK; Langslet G; Baccara-Dinet MT; Gipe DA; Chaudhari U; Zhao J; Minini P; Farnier M
    J Clin Lipidol; 2017; 11(1):195-203.e4. PubMed ID: 28391886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
    Ginsberg HN; Rader DJ; Raal FJ; Guyton JR; Baccara-Dinet MT; Lorenzato C; Pordy R; Stroes E
    Cardiovasc Drugs Ther; 2016 Oct; 30(5):473-483. PubMed ID: 27618825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
    Raal FJ; Kallend D; Ray KK; Turner T; Koenig W; Wright RS; Wijngaard PLJ; Curcio D; Jaros MJ; Leiter LA; Kastelein JJP;
    N Engl J Med; 2020 Apr; 382(16):1520-1530. PubMed ID: 32197277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
    Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
    J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.